Salarius (SLRX): חובות להיוון בספרים

Salarius Pharmaceuticals (SLRX) utilizes automated molecular screening to develop therapies, and the company's financial leverage trajectory clearly illustrates its current debt load. The value of 0.00 captures this metric while the business awaits the results of seclidemstat trials for Ewing sarcoma. High demand for rare pediatric oncology drugs opens significant market prospects for the issuer.

This indicator measures the ratio of total liabilities to equity, determining the extent of the business's reliance on debt financing. For Salarius Pharmaceuticals (SLRX), which lacks operating revenue, this calculation reflects the risk of resource depletion before the completion of clinical trials. The trend in the debt-to-capitalization ratio reflects the adaptation of the balance sheet structure to the cost of external loans. A decrease in the metric indicates a minimization of credit risks, while a high level of the indicator signals a critical vulnerability of capital to cost inflation.